Resources Repository
-
DataWeb Portal 2024Healthcare Cost and Utilization Project (HCUP)
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in …
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in the United States, including information on in-patient care, ambulatory care, and emergency department visits. HCUP enables researchers, insurers, policymakers and others to study health care delivery and patient outcomes over time, and at the national, regional, State, and community levels. The Agency for Healthcare Research and Quality (AHRQ) provides a range of data resources in the form of online, searchable…
Evidence Synthesis | Technology Assessment | Cost-Effectiveness Analysis | North America | Health Systems | Chronic Disease/Risk | Maternal/Reproductive Health | Infectious Diseases | Costing Methods | Health Outcomes | Test Performance | Child/Nutrition | Mental Health | Injuries/Accidents | Social Determinants | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | Science/Technology -
ArticlePublication 2018Should We Treat Acute Hepatitis C? A Decision and Cost-Effectiveness Analysis
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared …
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared to deferring treatment until the chronic phase, utilizing a microsimulation model. By projecting long-term outcomes such as quality-adjusted life years (QALYs) and costs, the analysis evaluates the cost-effectiveness of initiating therapy during the acute phase. Results indicate that treating acute HCV increases QALYs by 0.02 and costs by $483 per patient not at risk of transmitting HCV, yielding an incremental…
Cost-Effectiveness Analysis | Decision Analysis | North America | Chronic Disease/Risk | Infectious Diseases | Microsimulation | Health/Medicine -
ArticlePublication 2016An Economic Evaluation of the PEN Program in Indonesia
Responding to the economic and health burden of noncommunicable diseases (NCDs), the World Health Organization (WHO) …
Responding to the economic and health burden of noncommunicable diseases (NCDs), the World Health Organization (WHO) introduced the Package of Essential Noncommunicable disease (PEN) interventions. Several countries, including Indonesia, implemented the PEN program. To assess the value of the investment in the current program, an economic evaluation of the program was conducted with collaboration between the Ministry of Health in Indonesia, the WHO, and the International Decision Support Initiative (iDSI). This study evaluated the delivery of…
Technology Assessment | Cost-Effectiveness Analysis | Asia & Pacific | Health Systems | Chronic Disease/Risk | Priority Setting/Ethics | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2015A Conceptual Model for Breast, Cervical, and Colorectal Cancer Screening
General frameworks of the cancer screening process are available, but none directly compare the process …
General frameworks of the cancer screening process are available, but none directly compare the process in detail across different organ sites. This limits the ability of medical and public health professionals to develop and evaluate coordinated screening programs that apply resources and population management strategies available for one cancer site to other sites. This paper presents a conceptual model that incorporates a single screening episode for breast, cervical, and colorectal cancers into a unified framework based…
Evidence Synthesis | Cost-Effectiveness Analysis | North America | Health Systems | Chronic Disease/Risk | Preferences/Values | Health Outcomes | Test Performance | Microsimulation | Clinical Care | Health/Medicine | Science/Technology -
ArticlePublication 2022Comparing Health Gains, Costs & Cost-Effectiveness of Interventions in Australia & New Zealand
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New …
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New Zealand (NZ) from studies conducted with comparable methods, and reports results in the form of an online interactive league table. Studies from the Australia Cost-Effectiveness research and NZ Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programmes and studies were included which reported health-adjusted life years (HALYs) and net health system costs and/or incremental cost-effectiveness ratios, used a time horizon of…
Cost-Effectiveness Analysis | Asia & Pacific | Health Systems | Chronic Disease/Risk | Infectious Diseases | Priority Setting/Ethics | Mental Health | Health/Medicine | Oceania -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Cost-Effectiveness Analysis | North America | Health Systems | Chronic Disease/Risk | Infectious Diseases | Test Performance | State-Transition | Microsimulation | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Cost-Effectiveness Analysis | Asia & Pacific | Health Systems | Chronic Disease/Risk | Infectious Diseases | Health Outcomes | Mathematical Models | Calibration/Validation | Health/Medicine | Global | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean -
ArticlePublication 2008Health and Economic Implications of HPV Vaccination in the U.S.
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical …
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical carcinogenesis to compare the health and economic outcomes of vaccinating preadolescent girls in the US (at 12 years of age), and vaccinating older girls and women in catch-up programs (to 18, 21, or 26 years of age). The study also examined the health benefits of averting other HPV-16-related and HPV-18-related cancers, the prevention of HPV-6-related and HPV-11-related genital warts and…
Cost-Effectiveness Analysis | North America | Health Systems | Chronic Disease/Risk | Infectious Diseases | Dynamic Transmission | Microsimulation | Calibration/Validation | Clinical Care | Economics/Finance | Health/Medicine | Science/Technology -
ArticlePublication 2008Mathematical Models of Cervical Cancer Prevention in the Asia Pacific Region
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, …
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (I$/DALY averted) for vaccination of young adolescent girls against human papillomavirus (HPV) types 16 and 18. The authors used population-based and epidemiologic data for 25 countries in Asia (22 GAVI-Alliance eligible countries, Thailand, China and Japan). They found that an absolute reduction in lifetime cancer risk varied across countries, depending on incidence,…
Cost-Effectiveness Analysis | Asia & Pacific | Health Systems | Chronic Disease/Risk | Infectious Diseases | Mathematical Models | Microsimulation | Calibration/Validation | Economics/Finance | Health/Medicine | Science/Technology